1-20 of 57 results for subject:Psoriasis
Librarians' tools
- Search time
- 0.246 seconds
- Solr query time
- 0.003 seconds
- Search query
- subject:Psoriasis
- We searched for
- subject_t:Psoriasis OR subject_ses:429456
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into psoriasis in the 2023-24 financial year; and which public bodies provided that funding.
To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into psoriasis in the 2023-24 financial year; and which public bodies provided that funding.
The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR).
The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases.
UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development.
In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.
- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.
- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR | UKRI |
Acne | NIHR allocated £2,148,574.06 for research concerning acne research in 2023-24. | UKRI did not commit any specific funding for acne research in 2023-24. |
Alopecia | NIHR did not allocate any funds for research concerning alopecia research during 2023-24 | UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024. |
Psoriasis | NIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24. | UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 . |
Pemphigus | NIHR did not allocate any funds for research concerning pemphigus research during 2023-24 | UKRI did not commit any specific funding for pemphigus research in 2023-24. |
Atopic Dermatitis | NIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24. | UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023. |
Epidermolysis Bullosa | NIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24 | UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24. |
Hidradenitis Suppurativa | NIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24 | UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24. |
Scleroderma | NIHR allocated £155,575 for research concerning scleroderma research in 2023-24. | UKRI did not commit any specific funding for scleroderma research in 2023-24. |
Rosacea | NIHR did not allocate any funds concerning rosacea research during 2023-24 | UKRI did not commit any specific funding for rosacea research in 2023-24. |
Vitiligo | NIHR did not allocate any funds for research concerning vitiligo research during 2023-24 | UKRI did not commit any specific funding for vitiligo research in 2023-24. |
Basal Cell Carcinoma | NIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24 | UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24. |
Squamous Cell Carcinoma | NIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24 | UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24. |
Melanoma | NIHR allocated £1,167,536 for research concerning melanoma research in 2023-24 | UKRI have committed £176,114 for melanoma research between March 24 and August 25. |
Actinic Keratosis | NIHR did not allocate any funds concerning actinic keratosis research during 2023-24 | UKRI did not commit any specific funding for actinic keratosis research in 2023-24. |
To ask the Secretary of State for Health and Social Care, how many people aged between 16 and 25 are medically treated for psoriasis in England, broken down by (a) age and (b) gender.
To ask the Secretary of State for Health and Social Care, how many people aged between 16 and 25 are medically treated for psoriasis in England, broken down by (a) age and (b) gender.
A table showing a count of Finished Admission Episodes (FAEs) for patients aged 16 to 25 years old with a recorded primary diagnosis of psoriasis, broken down by patient age and gender, for the period 2019/20 to 2023/24, and in English National Health Service hospitals, is attached.
Please be aware that the majority of psoriasis is treated by a general practitioner or elsewhere in the community, with only a small minority of cases, typically the most serious, requiring hospital admission. The data presented will, therefore, only represent a small proportion of the total number of cases that were treated.
To ask the Secretary of State for Health and Social Care, whether her Department has taken recent steps to provide new medications for treating psoriasis on the NHS.
To ask the Secretary of State for Health and Social Care, whether her Department has taken recent steps to provide new medications for treating psoriasis on the NHS.
The Government wants all National Health Service patients to benefit from timely access to safe and effective new medicines in a way that represents value to the NHS. The National Institute for Health and Care Excellence (NICE) develops evidence-based guidance for the NHS on whether new medicines represent a clinically and cost-effective use of resources. NICE appraises all newly licensed medicines and aims to publish draft guidance around the time of licensing wherever possible. The NHS is legally required to fund medicines recommended by NICE, usually within three months of final guidance.
Since 2019, NICE has recommended several medicines for the treatment of patients with psoriasis meeting specified clinical criteria, including risankizumab, bimekizumab, tildrakizumab and deucravacitinib. The NHS is now legally required to routinely fund these treatments for eligible NHS patients in line with NICE’s recommendations.
To ask the Secretary of State for Health and Social Care, with reference to NHS Digital's publication on Hospital Outpatient Activity 2019-20, how many patients with (a) psoriasis and (b) atopic dermatitis attended outpatient appointments in (i) England and (ii) each commissioning region.
To ask the Secretary of State for Health and Social Care, with reference to NHS Digital's publication on Hospital Outpatient Activity 2019-20, how many patients with (a) psoriasis and (b) atopic dermatitis attended outpatient appointments in (i) England and (ii) each commissioning region.
The information is not available in the format requested.
To ask the Secretary of State for Health and Social Care, how many patients with (a) psoriasis and (b) atopic dermatitis were waiting longer than 18 weeks for care at the end of (i) 2018 (ii) 2019 and (iii) 2020.
To ask the Secretary of State for Health and Social Care, how many patients with (a) psoriasis and (b) atopic dermatitis were waiting longer than 18 weeks for care at the end of (i) 2018 (ii) 2019 and (iii) 2020.
Data is not held centrally in the format requested.
That this House notes that Psoriasis Awareness Week takes place between 29 October and 4 November 2020; recognises the vital work of the Psoriasis Association in continuing to provide information, support and help to all those affected by psoriasis and psoriatic arthritis during the covid-19 pandemic; further notes that this year’s Psoriasis Awareness Week will focus on types of psoriasis after identifying through the recent Priority Setting Partnership that there are many unrecognised knowns that have already been addressed by research but which are not familiar to patients and healthcare professionals; and calls on the Government to investigate ways to improve access to all relevant healthcare professionals for people with psoriasis whose essential treatment has been unfairly delayed by the impact of the recent covid-19 pandemic.
That this House notes that Psoriasis Awareness Week takes place between 29 October and 4 November 2020; recognises the vital work of the Psoriasis Association in continuing to provide information, support and help to all those affected by psoriasis and psoriatic arthritis during the covid-19 pandemic; further notes that this...
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of people with psoriasis.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of people with psoriasis.
No estimate has been made. However, the National Institute for Health and Care Excellence states that the prevalence of psoriasis have been estimated around 1.3 – 2.2% in the United Kingdom.
That this House recognises Psoriasis Awareness Week from 27 October – 3 November 2019 which this year aims to highlight how prospective parents can overcome the potential difficulties in treating psoriasis before, during and after childbirth; notes that the peak onset of psoriasis, which can affect as many as one in 50 people, occurs in those under the age of 25 years when people are beginning to consider their future family planning considerations and can have a devastating effect upon those plans; and calls upon the Government to investigate ways to improve access to all relevant healthcare professionals for people with psoriasis to help with planning for a family and to prevent some of the current delays in receiving effective therapies.
That this House recognises Psoriasis Awareness Week from 27 October – 3 November 2019 which this year aims to highlight how prospective parents can overcome the potential difficulties in treating psoriasis before, during and after childbirth; notes that the peak onset of psoriasis, which can affect as many as one...
To ask Her Majesty's Government how many patients with (1) suspected skin cancer, (2) psoriasis, and (3) atopic dermatitis were (a) referred by a GP, and (b) seen by a consultant dermatologist in England during the last 12 months.
To ask Her Majesty's Government how many patients with (1) suspected skin cancer, (2) psoriasis, and (3) atopic dermatitis were (a) referred by a GP, and (b) seen by a consultant dermatologist in England during the last 12 months.
This information is not available in the format requested.
To ask the Secretary of State for Health and Social Care, how many patients with (a) psoriasis, (b) atopic dermatitis and (c) hidradenitis suppurativa were seen by a dermatologist in 2018 in (i) Northern Lincolnshire and Goole NHS Foundation Trust and (ii) nationally.
To ask the Secretary of State for Health and Social Care, how many patients with (a) psoriasis, (b) atopic dermatitis and (c) hidradenitis suppurativa were seen by a dermatologist in 2018 in (i) Northern Lincolnshire and Goole NHS Foundation Trust and (ii) nationally.
No assessment has been made. The commissioning and configuration of dermatology services in England is a local matter. The local National Health Service is best placed to make decisions that ensure services meet the needs of resident populations in the most appropriate way. Health is a devolved matter, and as such, dermatology services in Wales, Scotland and Northern Ireland are a matter for the devolved administrations.
The majority of patients with dermatological disorders are managed in primary and community care. Whilst some patients may be referred for outpatient care, data collection here is not mandated, and is therefore partial and incomplete. Furthermore, the data that is available reports episodes of care, which are not a count of patients, as the same patient may have multiple episodes of care for the same reason.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the annual cost to the public purse of treating and managing (a) rheumatoid arthritis, (b) inflammatory bowel disease and (c) psoriasis.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the annual cost to the public purse of treating and managing (a) rheumatoid arthritis, (b) inflammatory bowel disease and (c) psoriasis.
No specific estimate has been made.
To ask the Secretary of State for Health and Social Care, how many children were being treated for psoriasis as of 1 May 2018.
To ask the Secretary of State for Health and Social Care, how many children were being treated for psoriasis as of 1 May 2018.
This information is not available.
To ask the Secretary of State for Health, how many men have been diagnosed with psoriasis in England in each of the last five years.
To ask the Secretary of State for Health, how many men have been diagnosed with psoriasis in England in each of the last five years.
Information concerning the number of men diagnosed with psoriasis in each of the last five years is not collected. The National Institute for Health and Care Excellence estimates that psoriasis affects around 2% of people in the United Kingdom.
To ask the Secretary of State for Health, what steps his Department is taking to ensure that patients with psoriasis are able to access the most effective NICE-approved treatment for their condition regardless of where they live in the country.
To ask the Secretary of State for Health, what steps his Department is taking to ensure that patients with psoriasis are able to access the most effective NICE-approved treatment for their condition regardless of where they live in the country.
The National Institute for Health and Care Excellence (NICE) has approved a number of different treatments for psoriasis as part of its technology appraisal (TA) programme, the most recent of these being Secukinumab, which was recommended as a possible treatment for people with plaque psoriasis in July 2015. The National Health Service is legally obliged to fund medicines and treatments recommended by NICE's TA programme, meaning people can access these treatments wherever they live in the country.
Information regarding the cost to the NHS of the continued treatment of psoriasis patients who do not achieve 75% skin clearance is not collected. The NICE best practice guideline Psoriasis: assessment and management, published in October 2012, covers approaches to diagnosis and treatment and specialist referral. The majority of TA recommended psoriasis treatments are featured in the guideline, and their success in treating psoriasis is measured using Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index. PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. In most cases, NICE defines an adequate response to treatment as one that includes a 75% reduction in a PASI score. The NICE guidance can be found at the following link:
www.nice.org.uk/guidance/cg153/resources/psoriasis-assessment-and-management-35109629621701
For patients who do not responded adequately to either topical treatment or biological therapies, such as those recommended by the NICE TA programme, the guidance recommends referral to a specialised service. NHS England commissions specialised dermatology services nationally and has set out what providers must have in place in order to deliver specialised dermatology care, as well as defining referral criteria. For psoriasis patients, referrals are appropriate where their condition is severe and they have not responded to NICE approved biological therapies. More information on specialised dermatology services can be found at the following link:
www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf
To ask the Secretary of State for Health, what the cost to the public purse is of NHS psoriasis patients continuing their current treatment who do not reach the NICE goal of 75 per cent skin clearance from treatment start.
To ask the Secretary of State for Health, what the cost to the public purse is of NHS psoriasis patients continuing their current treatment who do not reach the NICE goal of 75 per cent skin clearance from treatment start.
The National Institute for Health and Care Excellence (NICE) has approved a number of different treatments for psoriasis as part of its technology appraisal (TA) programme, the most recent of these being Secukinumab, which was recommended as a possible treatment for people with plaque psoriasis in July 2015. The National Health Service is legally obliged to fund medicines and treatments recommended by NICE's TA programme, meaning people can access these treatments wherever they live in the country.
Information regarding the cost to the NHS of the continued treatment of psoriasis patients who do not achieve 75% skin clearance is not collected. The NICE best practice guideline Psoriasis: assessment and management, published in October 2012, covers approaches to diagnosis and treatment and specialist referral. The majority of TA recommended psoriasis treatments are featured in the guideline, and their success in treating psoriasis is measured using Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index. PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. In most cases, NICE defines an adequate response to treatment as one that includes a 75% reduction in a PASI score. The NICE guidance can be found at the following link:
www.nice.org.uk/guidance/cg153/resources/psoriasis-assessment-and-management-35109629621701
For patients who do not responded adequately to either topical treatment or biological therapies, such as those recommended by the NICE TA programme, the guidance recommends referral to a specialised service. NHS England commissions specialised dermatology services nationally and has set out what providers must have in place in order to deliver specialised dermatology care, as well as defining referral criteria. For psoriasis patients, referrals are appropriate where their condition is severe and they have not responded to NICE approved biological therapies. More information on specialised dermatology services can be found at the following link:
www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf
To ask the Secretary of State for Health, pursuant to the Answer of 9 April 2014, Official Report, columns 261-3W, on psoriasis, what development to Read codes was found to be necessary by the Health and Social Care Information Centre to support the indicators proposed for psoriasis.
To ask the Secretary of State for Health, pursuant to the Answer of 9 April 2014, Official Report, columns 261-3W, on psoriasis, what development to Read codes was found to be necessary by the Health and Social Care Information Centre to support the indicators proposed for psoriasis.
The National Institute for Health and Care Excellence (NICE) Clinical Commissioning Group Outcome Indicator Set (CCG OIS) Advisory Committee considered the following draft psoriasis indicators, derived from the NICE Psoriasis Quality Standard, at its meeting in October 2014:
- PSO 5.1 Psoriasis: assessment for psoriatic arthritis;
- PSO 6.2 Skin disease: time off school or work due to skin disease;
- PSO 6.3 Psoriasis: skin clearance; and
- PSO 3.2 Psoriasis: Patient experience: access to secondary care services.
It was the decision of the committee that the indicators did not meet the prioritisation criteria, as set out in the NICE Indicator Process guide. The primary reason for this was that the majority of care for people with psoriasis is provided in primary care and the CCG OIS is focused on care provided in secondary care. As such, the committee has not put forward any of the psoriasis indicators for further development and testing by the Health and Social Care Information Centre (HSCIC). The HSCIC has not, therefore, undertaken any further work on the development of Read Codes for this topic.
The NICE indicator process guide and the NICE consultation document setting out those indicators which did meet the prioritisation criteria can be found at the links below:
www.nice.org.uk/media/03E/31/Indicators_process_guide.pdf
www.nice.org.uk/media/default/Standards-and-indicators/CCGOIS-indicator-consultation.pdf
To ask the Secretary of State for Health, pursuant to the Answer of 9 April 2014, Official Report, columns 261-3W, on psoriasis, what indicators have been proposed to the NICE Clinical Commissioning Group Outcomes Indicator Set Advisory Committee for psoriasis.
To ask the Secretary of State for Health, pursuant to the Answer of 9 April 2014, Official Report, columns 261-3W, on psoriasis, what indicators have been proposed to the NICE Clinical Commissioning Group Outcomes Indicator Set Advisory Committee for psoriasis.
The National Institute for Health and Care Excellence (NICE) Clinical Commissioning Group Outcome Indicator Set (CCG OIS) Advisory Committee considered the following draft psoriasis indicators, derived from the NICE Psoriasis Quality Standard, at its meeting in October 2014:
- PSO 5.1 Psoriasis: assessment for psoriatic arthritis;
- PSO 6.2 Skin disease: time off school or work due to skin disease;
- PSO 6.3 Psoriasis: skin clearance; and
- PSO 3.2 Psoriasis: Patient experience: access to secondary care services.
It was the decision of the committee that the indicators did not meet the prioritisation criteria, as set out in the NICE Indicator Process guide. The primary reason for this was that the majority of care for people with psoriasis is provided in primary care and the CCG OIS is focused on care provided in secondary care. As such, the committee has not put forward any of the psoriasis indicators for further development and testing by the Health and Social Care Information Centre (HSCIC). The HSCIC has not, therefore, undertaken any further work on the development of Read Codes for this topic.
The NICE indicator process guide and the NICE consultation document setting out those indicators which did meet the prioritisation criteria can be found at the links below:
www.nice.org.uk/media/03E/31/Indicators_process_guide.pdf
www.nice.org.uk/media/default/Standards-and-indicators/CCGOIS-indicator-consultation.pdf
To ask the Secretary of State for Health, pursuant to the Answer of 9 April 2014, Official Report, columns 261-3W, on psoriasis, what the conclusions were of the NICE Clinical Commissioning Group Outcomes Indicator Set Advisory Committee's review of potential indicators for psoriasis derived from the NICE Psoriasis Quality Standard.
To ask the Secretary of State for Health, pursuant to the Answer of 9 April 2014, Official Report, columns 261-3W, on psoriasis, what the conclusions were of the NICE Clinical Commissioning Group Outcomes Indicator Set Advisory Committee's review of potential indicators for psoriasis derived from the NICE Psoriasis Quality Standard.
The National Institute for Health and Care Excellence (NICE) Clinical Commissioning Group Outcome Indicator Set (CCG OIS) Advisory Committee considered the following draft psoriasis indicators, derived from the NICE Psoriasis Quality Standard, at its meeting in October 2014:
- PSO 5.1 Psoriasis: assessment for psoriatic arthritis;
- PSO 6.2 Skin disease: time off school or work due to skin disease;
- PSO 6.3 Psoriasis: skin clearance; and
- PSO 3.2 Psoriasis: Patient experience: access to secondary care services.
It was the decision of the committee that the indicators did not meet the prioritisation criteria, as set out in the NICE Indicator Process guide. The primary reason for this was that the majority of care for people with psoriasis is provided in primary care and the CCG OIS is focused on care provided in secondary care. As such, the committee has not put forward any of the psoriasis indicators for further development and testing by the Health and Social Care Information Centre (HSCIC). The HSCIC has not, therefore, undertaken any further work on the development of Read Codes for this topic.
The NICE indicator process guide and the NICE consultation document setting out those indicators which did meet the prioritisation criteria can be found at the links below:
www.nice.org.uk/media/03E/31/Indicators_process_guide.pdf
www.nice.org.uk/media/default/Standards-and-indicators/CCGOIS-indicator-consultation.pdf
To ask the Secretary of State for Health what discussions he has had with NHS trusts on the prescription of medicines for psoriasis.
To ask the Secretary of State for Health what discussions he has had with NHS trusts on the prescription of medicines for psoriasis.
We have had no such discussions.
Information on the prescription of medicines for psoriasis is available from a range of sources including the British National Formulary, the National Institute for Health and Care Excellence and NHS Choices.
To ask the Secretary of State for Health (1) what data requirements are necessary to precipitate the development of Clinical Commissioning Group Outcome Indicators based on quality statements 1 and 2 of the NICE quality standard on psoriasis;
To ask the Secretary of State for Health (1) what data requirements are necessary to precipitate the development of Clinical Commissioning Group Outcome Indicators based on quality statements 1 and 2 of the NICE quality standard on psoriasis;
I refer the right hon. Member to the written answer I gave her on 9 April 2014, Official Report, columns 262-63W.